PEOPLE HAD HEADACHES
IDELVION Connectsm patient support program
Get IDELVION news that matters to you
Call 1-800-676-4266
Monday–Friday,
8 am to 8 pm ET
Only 7 of the 114 (6%) previously treated individuals in clinical trials experienced side effects.
PEOPLE HAD DIZZINESS
PERSON HAD
RASH
PERSON HAD ECZEMA
PERSON HAD
HYPERSENSITIVITY REACTION
THE SAFETY OF IDELVION WAS ALSO EVALUATED IN A COMPLETED STUDY WITH 12 PUPS*
Adverse drug reactions were reported in 2 of 12 patients treated with IDELVION
- 1 patient (8.3%) developed a high titer of FIX inhibitors (peak titer 188 BU/mL) and the same patient developed hypersensitivity
- 1 patient (8.3%) developed rash
* Exposure days (EDs): Median number of EDs was 50 (range: 22 to 146) per patient. 8 patients achieved at least 50 EDs, of whom 3 patients achieved ≥100 EDs.
PUPs, Previously Untreated Patients